Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Helminths and mucosal immune modulation.

Weinstock JV.

Ann N Y Acad Sci. 2006 Aug;1072:356-64. Review.

PMID:
17057216
2.

Current limitations of IBD treatment: where do we go from here?

Targan SR.

Ann N Y Acad Sci. 2006 Aug;1072:1-8. Review.

PMID:
17057185
3.

Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease.

Seksik P, Sokol H, Lepage P, Vasquez N, Manichanh C, Mangin I, Pochart P, Doré J, Marteau P.

Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:11-8. Review.

4.

Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency.

Mannon PJ, Fuss IJ, Dill S, Friend J, Groden C, Hornung R, Yang Z, Yi C, Quezado M, Brown M, Strober W.

Gastroenterology. 2006 Sep;131(3):748-56.

PMID:
16952544
5.

Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis.

Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W.

Immunity. 2006 Sep;25(3):473-85. Epub 2006 Aug 31.

6.

A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.

Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF.

Am J Hum Genet. 2006 Sep;79(3):439-48. Epub 2006 Jul 12.

7.

Role of toll-like receptors in spontaneous commensal-dependent colitis.

Rakoff-Nahoum S, Hao L, Medzhitov R.

Immunity. 2006 Aug;25(2):319-29. Epub 2006 Aug 3.

8.

The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients.

Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW.

J Med Microbiol. 2006 Aug;55(Pt 8):1141-9.

PMID:
16849736
9.

Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.

Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB.

J Clin Gastroenterol. 2006 Jul;40(6):482-9.

PMID:
16825929
10.

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L.

Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9. Epub 2006 May 22.

PMID:
16716759
12.

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.

Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D.

J Clin Invest. 2006 May;116(5):1310-6.

13.

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr.

Aliment Pharmacol Ther. 2006 May 15;23(10):1415-25.

14.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.

Gut. 2006 Nov;55(11):1568-74. Epub 2006 Apr 7.

15.

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.

Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T.

Gut. 2006 Aug;55(8):1131-7. Epub 2006 Feb 28.

16.

Signalling pathways and molecular interactions of NOD1 and NOD2.

Strober W, Murray PJ, Kitani A, Watanabe T.

Nat Rev Immunol. 2006 Jan;6(1):9-20. Review.

PMID:
16493424
17.

ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach.

Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J.

Hum Mol Genet. 2006 Mar 1;15(5):797-805. Epub 2006 Jan 24.

PMID:
16434479
18.

Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype.

Hussain N, Quezado M, Huizing M, Geho D, White JG, Gahl W, Mannon P.

Clin Gastroenterol Hepatol. 2006 Jan;4(1):73-80.

PMID:
16431308
19.

Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.

Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ.

Inflamm Bowel Dis. 2006 Jan;12(1):9-15.

PMID:
16374252
20.

Infliximab for induction and maintenance therapy for ulcerative colitis.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF.

N Engl J Med. 2005 Dec 8;353(23):2462-76. Erratum in: N Engl J Med. 2006 May 18;354(20):2200.

Supplemental Content

Support Center